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Brief Technique ReportsRadiolucent retractor for angiographic analysis during hybrid
congenital cardiac proceduresGareth J. Morgan, MB, BaO, BCh, MRCPCH, MPhil, Karen Clarke, RN, Christopher Caldarone, MD, and
Lee N. Benson, MD, FRCPC, Toronto, Ontario, CanadaManagement of congenital heart disease by using a combi-
nation of surgical and interventional cardiology skills is
a growing field, and as such, many technical innovations
are being described.1-4
One key area is the interplay between the sterile surgical
field and the imaging equipment required for angiographic
analysis. Stable positioning of surgical clamps, drains, and re-
tractors can be challenging to adjust for high-quality imaging
of the anatomy. As part of a strategy to improve the proce-
dure, our group has devised and implemented a radiolucent
sternal retractor (Finochietto infant retractor design) to allow
improved angiographic visualization without compromising
the surgical field.FIGURE 2. The radiolucent retractor in use during a stage 2 hybrid hypo-
plastic left heart syndrome procedure. The projection is a straight posteroan-
terior with the catheter placed in the Glenn anastomosis directly through theDISCUSSION
The dimensions of the radiolucent spreader are identical
to a standard steel infant Finochietto retractor; however,
the device is constructed almost entirely from polyetheri-FIGURE 1. Left, The thermoplastic radiolucent Finochietto infant retractor. Rig
left heart syndrome. Note the 6F sheath placed through the chest into the main
open chest. The arms of the retractor can just be delineated, allowing angio-
graphic visualization of the innominate vein and distal branch pulmonary
arteries. A significant stenosis of the left pulmonary artery can be seen.
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The Journal of Thoracic and Carmide, a thermoplastic with excellent machinability and me-
chanical properties, which is also heat stable for sterilization
in an autoclave (Figure 1). A part of the hinge mechanism is
made from stainless steel to ensure longevity and maintain
smooth operation of the hinge over multiple procedures.
Its radiolucency aids the ease and quality of the angiographic
analysis (Figure 2). We believe that innovative solutionsht, The retractor in use during stage 1 of a hybrid procedure for hypoplastic
pulmonary artery for ductal stent placement.
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Brief Technique Reportssuch as this are important in the continued development of
hybrid technologies for use in patients with in congenital
and structural heart disease.References
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2010;139:1211-5.Palliative role of percutaneous radiofrequency ablation for severe
hemoptysis in an elderly patient with inoperable lung cancerAlessandro Baisi, MD,a Federico Raveglia, MD,a Matilde De Simone, MD, PhD,b and
Ugo Cioffi, MD, PhD,b Milan, ItalySurgical resection remains the standard therapeutic treat-
ment for patients with resectable non–small cell lung cancer
and for selected patients with limited pulmonary metastases
from extrathoracic tumors, even if only a small number of
patients are suitable for potentially curative resection.1,2 Per-
cutaneous image-guided radiofrequency ablation (RFA) is
a minimally invasive therapeutic option that has been suc-
cessfully applied to local control of tumors in different or-
gans including the lung.3,4 This technique has recently
been recognized as the primary therapy in patients who are
not candidates for limited surgery or radiotherapy and can
be used to treat recurrent lesions.4 The procedure is well tol-
erated and the complication rate is acceptable even when
considering the treatment of large masses.4,5 We report
a case of an elderly patient with advanced lung cancer lead-
ing to severe and recurring hemoptysis that was successfully
treated with RFA.CLINICAL SUMMARY
An 82-year-old woman was referred to our department
with right lung cancer complicated by severe and recurring
hemoptysis necessitating repeated blood transfusions. The
tumor was 63 6 cm in size, located in the peripheral paren-chyma of the lower lobe, with pathologic hilar and medias-
tinal lymph nodes. Three months earlier, she had been
excluded from both surgery and medical treatment owing
to the tumor stage (IIIB) and respiratory and cardiac comor-
bidities. Several bronchoscopic examinations were per-
formed showing blood in the airways without any evident
endobronchial source of the bleeding. Endobronchial cauter-
ization was unfeasible to control the hemoptysis because
there was no evident endobronchial source of the bleeding.
No bronchial or pulmonary vessels supplying the mass
were identified in an arteriogram, and embolization was
also impossible. In the hope of controlling the bleeding by
sclerosing the tumor, we attempted a percutaneous RFA, de-
spite the size of the mass and the tumor stage. The procedure
was performed under a nonenhanced computed tomographic
(CT) scan by RF 3000 Radiofrequency Generator with
a 16-gauge, 15-cm long, 4.0-cm array diameter LeVeen
CoAssess Electrode (Radiotherapeutics, Boston Scientific
Corporation, Natick, Mass), starting from 30 up to 160 watts
(Figure 1) and repeated more in depth in the mass starting
from 30 up to 120 watts (Figure 2). The hemoptysis was suc-
cessfully controlled after the procedure. A minimal pleural
effusion without pneumothorax occurred. At the 6-month
follow-up, the patient was free from bleeding and the mass
was reduced to 5 3 5 cm. One year after the procedure the
patient died of distant metastases.DISCUSSION
The safety and feasibility of percutaneous RFA for un-
resectable lung cancers have now been considered by sev-
eral authors.1,2,5 Survival time and efficacy of the
procedure are significantly longer in patients with com-
pletely ablative tumors.2 Tissue ablation adequacy dependsgery c November 2010
